IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
CM Sweeney, R Lonergan, SA Basdeo… - Brain, behavior, and …, 2011 - Elsevier
Interferon (IFN)-β is a commonly used therapy for relapsing remitting multiple sclerosis
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
[引用][C] IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
CM Sweeney, R Lonergan, SA Basdeo… - Brain, Behavior, and …, 2011 - cir.nii.ac.jp
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17
cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
CM Sweeney, R Lonergan, SA Basdeo… - Brain, Behavior, and …, 2011 - europepmc.org
Interferon (IFN)-β is a commonly used therapy for relapsing remitting multiple sclerosis
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
CM Sweeney, R Lonergan… - Brain, behavior …, 2011 - pubmed.ncbi.nlm.nih.gov
Interferon (IFN)-β is a commonly used therapy for relapsing remitting multiple sclerosis
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
[PDF][PDF] IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
CM Sweeney, R Lonergan, SA Basdeo, K Kinsella… - 2011 - tara.tcd.ie
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by
inhibiting Th17 cells Page 1 Accepted Manuscript IL-27 mediates the response to IFN-β therapy …
inhibiting Th17 cells Page 1 Accepted Manuscript IL-27 mediates the response to IFN-β therapy …
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
CM Sweeney, R Lonergan, SA Basdeo… - Brain Behavior and …, 2011 - infona.pl
Interferon (IFN)-β is a commonly used therapy for relapsing remitting multiple sclerosis
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …